Climb Bio Elects New Board Members at Annual Meeting

An announcement from Climb Bio ( (CLYM) ) is now available.

On June 4, 2025, Climb Bio, Inc. held its Annual Meeting of Stockholders where significant decisions were made regarding the company’s leadership and auditing practices. At the meeting, stockholders elected Judith Dunn, Ph.D., and Stephen Thomas, Ph.D., to the board of directors for a three-year term, and ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CLYM) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.

Spark’s Take on CLYM Stock

According to Spark, TipRanks’ AI Analyst, CLYM is a Neutral.

Climb Bio’s stock score is primarily driven by its financial performance, reflecting the company’s developmental challenges with negative income and cash flow. Despite strong equity and cash reserves, the technical indicators show a bearish trend, and the valuation reflects typical early-stage biotech characteristics with a negative P/E ratio. The absence of significant earnings call data or corporate events means the focus remains on financial stability and potential for future growth.

To see Spark’s full report on CLYM stock, click here.

More about Climb Bio

Average Trading Volume: 154,808

Technical Sentiment Signal: Sell

Current Market Cap: $87.17M

See more data about CLYM stock on TipRanks’ Stock Analysis page.